Home›Clinical trials›Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Enrolling now · NCT07223593

A study testing whether a GLP-1 medicine from Lilly, orforglipron, can improve blood flow in the legs.

What this means for you

Who can join
Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.
What you take
orforglipron, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts
The full study runs about 2.7 years; your own time in it is usually shorter.
What you get
The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
Phase Phase 3Sponsor Eli Lilly and CompanyDrug orforglipronClass GLP-1 RASites 30 USEnrollment target 1,205

What this study is for

Primary condition: Peripheral Arterial Disease.

Full scientific study title: Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease.

Who can join

Age18 and upSexAnyBMI23 or higher

Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Have symptomatic PAD with intermittent claudication of Fontaine Stage II
  • Have an Ankle Brachial Index (ABI) of 0.9 or less

Key exclusion criteria

  • Have a body mass index (BMI) less than 23 kilogram per square meter (kg/m2)
  • Have Hemoglobin A1c (HbA1c) greater than 10%
  • Have walking ability limited by conditions other than PAD
  • Have a planned lower limb surgery or any other surgery affecting walking ability
  • Had peripheral revascularization procedure within 90 days prior to the day of screening or planning to undergo peripheral revascularization during the clinical trial

Where this study is enrolling

This trial has 30 sites across 13 states. Contact a site coordinator directly to start screening.

Alabama1 site
  • St. Vincent's Birmingham Hospital
    Birmingham, Alabama
Arizona3 sites
  • Mercy Gilbert Medical Center
    Gilbert, Arizona
    602-214-0886
  • Axsendo Clinical Research - Peak Heart & Vascular - Surprise
    Surprise, Arizona
    844-290-2273
  • Del Sol Research Management, LLC
    Tucson, Arizona
    520-257-3881
California4 sites
  • Valley Clinical Trials, Inc.
    Northridge, California
    818-280-4220
  • The Cardiovascular Center
    Redding, California
    281-944-3610
  • InvivoCure
    Van Nuys, California
    859-509-0084
  • Interventional Cardiology Medical Group
    West Hills, California
    818-702-8800
Florida4 sites
  • Lakeview Institute of Clinical Research
    Leesburg, Florida
    352-782-0606
  • Inpatient Research Clinic
    Miami Lakes, Florida
    786-502-4303
  • Floridian Clinical Research, LLC
    Miami Lakes, Florida
    305-330-9977
  • St Johns Center for Clinical Research
    Saint Augustine, Florida
    904-209-0043
Indiana3 sites
  • ASHA Clinical Research - Munster, LLC
    Hammond, Indiana
    219-803-6649
  • Indiana University Health Methodist Hospital
    Indianapolis, Indiana
  • Deaconess Clinic- Gateway
    Newburgh, Indiana
    812-490-4505
Maryland1 site
  • Flourish Research - Bowie
    Bowie, Maryland
    410-824-1341
Michigan1 site
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
    Troy, Michigan
    248-312-0025
Pennsylvania1 site
  • Capital Area Research, LLC
    Camp Hill, Pennsylvania
    717-441-1725
Tennessee2 sites
  • The Jackson Clinic
    Jackson, Tennessee
    731-660-8396
  • East Coast Institute for Research - Jefferson City
    Jefferson City, Tennessee
Texas4 sites
  • Biopharma Informatic, LLC
    Houston, Texas
    281-944-3610
  • Research Physicians Network, LLC
    Houston, Texas
    832-847-1724
  • Sherman Clinical Research
    Sherman, Texas
    903-771-4093
  • NextStage Clinical Research - Waco
    Waco, Texas
Utah1 site
  • Alpine Research Organization
    Clinton, Utah
    801-791-2206
Virginia3 sites
  • Stroobants Cardiovascular Center
    Lynchburg, Virginia
  • Clinical Research Partners, LLC
    Richmond, Virginia
    804-477-3045
  • Gershon Pain Specialists
    Virginia Beach, Virginia
    757-496-2050
Washington2 sites
  • ERA Health Research - CardioNow - Lynnwood
    Lynnwood, Washington
    425-869-6828
  • Eastside Research Associates
    Redmond, Washington
    425-869-6828

Timeline

Started enrolling: 2025-10-31. Expected completion: 2028-06. Last updated on ClinicalTrials.gov: 2026-05-22.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact
Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page weekly.